University of Kansas Medical Center, School of Nursing, Kansas City, Kansas.
University of Kansas Medical Center, School of Nursing, Kansas City, Kansas.
Am J Cardiol. 2022 Aug 1;176:79-88. doi: 10.1016/j.amjcard.2022.04.031. Epub 2022 May 27.
Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or d-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/or d-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF. This was a phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF who were ≥ 50 years old with a left ventricular ejection fraction (EF) ≥ 50%. A total of 4 study groups received various supplements over 12 weeks: Group 1 received placebo ubiquinol capsules and d-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder, Group 3 received placebo ubiquinol capsules with d-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and d-ribose powder. There were 7 outcome measures for this study: Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, level of vigor using a subscale from the Profile of Mood States, EF, the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e' ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio, and the 6-minute walk test. Treatment with ubiquinol and/or d-ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to 8.03%) and reduced B-type natriuretic peptides (-72.02 to -47.51) and lactate/adenosine triphosphate ratio (-4.32 to -3.35 × 10). There were no significant increases in the septal E/e' or the 6-minute walk test. In conclusion, ubiquinol and d-ribose reduced the symptoms of HFpEF and increased the EF. These findings support the use of these supplements in addition to standard therapeutic treatments for patients with HFpEF.
患有射血分数保留型心力衰竭（HFpEF）的患者几乎没有药物治疗选择，目前尚不清楚补充泛醇和/或 D-核糖是否能改善预后。本研究的总体目标是确定泛醇和/或 D-核糖是否会减轻 HFpEF 患者的症状并改善心功能。这是一项 216 例 HFpEF 患者的 2 期随机、双盲、安慰剂对照试验，患者年龄均≥50 岁，左心室射血分数（EF）≥50%。共有 4 个研究组在 12 周内接受了各种补充剂治疗：第 1 组接受安慰剂泛醇胶囊和 D-核糖粉，第 2 组接受泛醇胶囊（600mg/d）和安慰剂 D-核糖粉，第 3 组接受安慰剂泛醇胶囊和 D-核糖粉（15g/d），第 4 组接受泛醇胶囊和 D-核糖粉。本研究有 7 个观察结果：堪萨斯城心肌病问卷（KCCQ）临床综合评分、心境状态量表子量表的活力水平、EF、二尖瓣峰值充盈速度与早期舒张期二尖瓣环速度的比值（间隔 E/e'比值）、B 型利钠肽、乳酸/三磷酸腺苷比值和 6 分钟步行试验。泛醇和/或 D-核糖治疗可显著改善 KCCQ 临床综合评分（17.30 分至 25.82 分）、活力评分（7.65 分至 8.15 分）和 EF（7.08%至 8.03%），并降低 B 型利钠肽（-72.02 分至-47.51 分）和乳酸/三磷酸腺苷比值（-4.32 分至-3.35×10）。间隔 E/e'或 6 分钟步行试验无显著增加。总之，泛醇和 D-核糖可减轻 HFpEF 的症状并提高 EF。这些发现支持在 HFpEF 患者的标准治疗基础上使用这些补充剂。
